Similarly, in terms of HPV‐independent tumors, alterations in the p53 pathway have been identified in ROS1‐mutated NSCLC, where they have been implicated in treatment resistance, prognosis, and tumor progression [13]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.